Innovative NeuroTechnologies, Inc.

Innovative NeuroTechnologies, Inc. (INT) is a development-stage biotechnology company operating in “virtual mode” that is currently pursuing a pipeline of novel biologically-based and disease-modifying therapeutic solutions to prevent, delay, or mitigate the underlying dementia or cognitive decline associated with a spectrum of neurodegenerative disorders referred to as tauopathies, which includes: • Alzheimer’s disease (AD), • Frontotemporal dementia (FTD or Pick’s disease), • Chronic traumatic encephalopathy (CTE) or dementia pugilistica, • Progressive supranuclear palsy (PSP), • Corticobasal degeneration (CBD), • Familial form of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and • Parkinson's disease dementia (PDD). The pathology of these seemingly disparate conditions is similar in that they involve dysregulation of the Tau protein and development of neurofibrillary tangles (NFTs), synaptic dysfunction, and/or neuronal loss, which underlie the observed dementia or cognitive deficits. Unfortunately, there are no effective therapies presently available for this spectrum of disorders, and neurodegenerative tauopathies remain a very significant socioeconomic burden and tremendous unmet medical need worldwide.